Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Lucinactant

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Windtree Announces Results from Its Phase 2 Study of Lucinactant for COVID-19
    Windtree Announces Results from Its Phase 2 Study of Lucinactant for COVID-19

    22 Mar 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/03/22/2407470/0/en/Windtree-Announces-Results-from-Its-Phase-2-Study-of-Lucinactant-for-COVID-19-Associated-Acute-Respiratory-Distress-Syndrome-ARDS-and-Lung-Injury.html

    GLOBENEWSWIRE
    22 Mar 2022
    Share Share
    Windtree Completes Enrollment in Phase 2 Study of Lucinactant
    Windtree Completes Enrollment in Phase 2 Study of Lucinactant

    01 Feb 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/02/01/2376571/0/en/Windtree-Completes-Enrollment-in-Its-Phase-2-Study-of-Lucinactant-KL4-Surfactant-for-COVID-19-Associated-Lung-Injury-and-Acute-Respiratory-Distress-Syndrome.html

    GLOBENEWSWIRE
    01 Feb 2022
    Share Share
    Windtree Announces FDA Acceptance of IND Application for a Ph2 Trial
    Windtree Announces FDA Acceptance of IND Application for a Ph2 Trial

    29 Sep 2020

    // INVESTORROOM

    http://windtreetx.investorroom.com/2020-09-29-Windtree-Announces-FDA-Acceptance-of-IND-Application-for-a-Phase-2-Clinical-Trial-Studying-KL4-Surfactant-in-Acute-Lung-Injury-in-Adults-with-COVID-19

    INVESTORROOM
    29 Sep 2020
    Share Share